A randomized, parallel-group, phase 2 dose-finding study to evaluate the effects of BA058 in the treatment of postmenopausal women with osteoporosis

Trial Profile

A randomized, parallel-group, phase 2 dose-finding study to evaluate the effects of BA058 in the treatment of postmenopausal women with osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2015

At a glance

  • Drugs Abaloparatide (Primary) ; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Mar 2015 Post hoc analysis (Trabecular Bone Score) results presented at The 97th Annual Meeting of the Endocrine Society.
    • 24 Nov 2014 Results published in a Radius Health media release and also published online in the Journal of Clinical Endocrinology & Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top